Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu

Cancer Research

Volumn 56, Issue 4, 1996, Pages 794-801

  Tsai, Chun Ming ^a,b   Chang, Kuo Ting ^b   Chen, Jeou Yuan ^a   Chen, Yuh Min ^a,b   Chen, Mei Hui ^b   Perng, Reury Perng ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE;

ARTICLE; CELL SURVIVAL; CROSS RESISTANCE; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; RECEPTOR, ERBB-2; REGRESSION ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0030019658     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Minna, J D., Pass, H., Glatstein, E., and Ihde, D. C. Cancer of the lung. In: V. T. Devita, Jr., S. Hellman, and S. A. Rosenberg (eds), Cancer Principles and Practice of Oncology, pp. 673-722. Philadelphia: J B Lippincott Co., 1993.
2. Shepherd, F. A. Treatment of advanced non-small cell lung cancer. Semin. Oncol , 21 (Suppl. 7) 7-18, 1994.
3. Tsai, C. M , Ihde, D. C., Kadoyama, C., Venzon, D., and Gazdar, A F Correlation of in vitro drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival. Eur. J Cancer, 26: 1148-1152, 1990.
4. Gazdar, A. F., Kadoyama, C., Venzon, D , Park, J G., Tsai, C. M., Linnoila, R I , Mulshine, J. L., Ihde, D. C., and Giaccone, G. The effects of histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J. Natl Cancer Inst. Monogr., 13: 191-196, 1992
5. Campling, B. G , Baker, H. M., Pym, J., Gerlach, J. H., Cole, S. P C., and Lam, Y. M Patterns of drug responsiveness in small cell lung cancer. Proc. Am. Assoc. Cancer Res., 33: 491, 1992.
6. Tsai, C M , Chang, K. T, Perng, R P., Mitsudomi, T., Chen, M H., Kadoyama, C , and Gazdar, A F. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations J Natl Cancer Inst., 85. 897-901, 1993.
7. neu-expressing human non-small cell lung cancer cell lines. J. Natl. Cancer Inst , 86: 1018-1020, 1994
8. Tsai, C. M., Chang, K. T , Wu, L. H , Chen, J. Y., Gazdar, A F , Mitsudomi, T., Chen, M H., and Perng, R P Correlations between intrinsic chemoresistance and HER-2/ neu gene expression p53 gene mutations and cell proliferation characteristics in non-small cell lung cancer cell tines. Cancer Res , 56: 206-209, 1996.
9. Coussens, L., Yang-Feng, T. L , Liao, Y. C , Chen, E , Gray, A., McGrath, J , Seeburg, P. H , Libermann, T., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
10. Schneider, P. M., Hung, M. C , Chiocca, S M., Manning, J., Zhao, X., Fang, K., and Roth, J. A. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res., 49: 4968-4971, 1989.
11. Shi, D., He, G., Gao, S., Pan, W , Zhang, H X., Yu, D., and Hung, M C Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer Mol. Carcinog., 5, 213-218, 1992.
12. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50: 5184-5191, 1990.
13. neu in the HER-2/neu transfected human lung cancer cells J. Natl Cancer Inst., 87. 682-684, 1995.
14. Smythe, C., Newport, J. W. Coupling of mitosis to the completion of S phase in Xenopus occurs via modulation of the tyrosine kinase that phosphorylates p34cdc2. Cell, 68: 787-797, 1992.
15. Schlegel, R., and Pardee, A. Caffeine induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science (Washington DC), 232: 1264-1266, 1986.
16. 2-arrest in Chinese hamster ovary cells treated with anticancer drugs J. Natl. Cancer Inst , 57: 1139-1143, 1976.
17. 2 arrest in Chinese hamster ovary cells Cancer Res., 50: 3761-3766, 1990.
18. Hertel, L. W , Boder, G. B., Kroin, J S., Rinzel, S. M , Poore, G. A., Todd, G C., and Grindey, G. B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res, 50, 4417-4422, 1990.
19. Heinemann, V., Hertel, L W., Grady, G. B., and Plunkett, W. Comparison of the cellular pharmacokinedcs and toxicity of 2′,2′-difluoro-2′-deoxycytidine and 1-β-D-arabinofuranosylcystosine. Cancer Res., 48: 4024-4031, 1988.
20. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluoro-2′-deoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
21. Baker, C H , Banzon, J., Bollinger, J. M , Stubbe, J , Samano, V., Robins, M. J., Lippen, B., Jarvi, E., and Resvick, R 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphate Potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem., 34: 1879-1884, 1991.
22. Xu, Y. Z., and Plunkett, W. Regulation of dCMP deaminase in intact CCRF-CEM cells. Proc. Am. Assoc Cancer Res., 30: 405, 1990
23. Tsai, C. M., Gazdar, A F., Venzon, D J., Steinberg, S. M , Dedrick, R L., Mulshine, J. L., and Kramer, B. S. Lack of in vitro synergy between etoposide and cis-diammine-dichloroplatinum(II). Cancer Res., 49: 2390-2397, 1989
24. Durand, R. E., and Vanderbyl, S. L. Schedule dependence for cisplatin and etoposide multifraction treatments of spheroids. J. Natl Cancer Inst., 82: 1841-1845, 1990.
25. Kondo, H., Kanzawa, F , Nishio, K., and Saijo, N. In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines. Jpn. J. Cancer Res , 85. 1050-1056, 1994.
26. Tsai, C. M., Gazdar, A. F., Perng, R P , and Kramer, B. S. Schedule dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines Int J. Cancer, 47. 401-407, 1991
27. Tsai, C. M., Shiao, S. H., Frey, C. M., Chang, K. T., Perng, R. P., Gazdar, A. F., and Kramer, B. S Combination cytotoxic effects of cis-diamminedichloro-platinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines. Cancer Res., 53: 1079-1084, 1993.
28. Berenbaum, M C. Synergy, additivism and antagonism in immunosuppression: a critical review. Clin. Exp. Immunol., 28: 1-18, 1977.
29. Frey, C. M. Role of modeling in joint action studies. J. Natl. Cancer Inst., 86: 1493-1495, 1994.
30. Lilenbaum, R. C., and Green, M. R. Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J. Clin. Oncol., 7. 1391-1402, 1993.
31. Yang, L. Y., Liu, L. L., Keating, X. M., and Plunkett, M. J. Gemcitabine suppress the repair of cisplatin adducts in plasmid DNA by extracts of cisplatin-resistant human colon carcinoma cells. Proc. Am. Assoc Cancer Res., 35. 357, 1995.
32. Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., and Slamon, D J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells Oncogene, 9: 1829-1838, 1994.
33. Kaye, S. B. Gemcitabine: current status of phase I and II trials. J. Clin. Oncol., 12: 1527-1531, 1994
34. Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., and Rugg, T. A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study J. Clin. Oncol. 12: 1535-1540, 1994
35. Anderson, H , Lund, B., Bach, F , Thatcher, N., Walling, J , and Hansen, H. H. Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II trial J. Clin. Oncol., 12: 1821-1826, 1994.
36. Cormier, Y., Shepherd, F., Burkes, R., Crump, M., Feld, R., and Strack, T. Phase I study of gemcitabine and cisplatin for advanced non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol., 13: 342, 1994.
37. Steward, W P., Dunlop, D. J., Cameron, C., Talbot, D. C., Kleisbauer, J. P., Thomas, P , Guerin, J. C., Perol, M., Sanson, C., Dabouis, G., and Lacroix, H. Phase I/II study of cisplatin in combination with gemcitabine in non-small-cell lung cancer (Abstract). Proc. Am. Soc. Clin. Oncol., 14: 351, 1995.
38. Crino, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., DeMarinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Cocconi, G , Paccagnella, A., Adamo, V , Incoronato, P., Scarcella, L., Mosconi, A. M., and Tonato, M. Cisplatin-gemcitabine combination in non-small cell lung cancer: a phase II study (Abstract) Proc. Am. Soc. Clin. Oncol., 14: 352, 1995.
39. Sandler, A. B., Ansari, R., McClean, J., Fisher, W , Dorr, A., and Einhorn, L. H. A Hoosier Oncology Group phase B study of gemcitabine plus cisplatin in non-small cell lung cancer (Abstract). Proc. Am. Soc Clin. Oncol., 14: 357, 1995.
40. Abratt, R P., Bezwoda, W. R , Goedhals, L., and Hacking, D. J. A phase II study of gemcitabine with cisplatin in patients with non-small cell lung cancer (Abstract). Proc. Am. Soc. Clin. Oncol., 14: 375, 1995.